Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer’s Alok Kanti On Price Cuts And Lower-tier Markets In China: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

In his first public interview since assuming leadership for Bayer Healthcare China in July, Alok Kanti discusses Bayer’s strategy in China.

You may also be interested in...



Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt

With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics

SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts

As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In Rising China

BEIJING - German pharmaceutical powerhouse Bayer Schering is engineering an alliance with Chinese scientists to create a global research and development center in Beijing, according to senior Bayer executives

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC079752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel